Found 14 Ovarian Cancer trials
A listing of Ovarian Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
To evaluate the safety and tolerability of STRO-002/bevacizumab as a combination therapy. To further evaluate the toxicity and tolerability of STRO-002/bevacizumab in patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) To characterize the PK of STRO-002 when administered with bevacizumab To assess the immunogenic potential …
This study has two parts: Part 1 (dose escalation) and Part 2 (dose expansion). The purpose of Part 1 is to determine: What effects, good and/or bad, STRO-002 has on subjects and their disease The highest dose of STRO-002 that can be safely given to subjects using a pre-defined starting …
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
This is a small scale investigational study to compare different fluorescent camera imaging systems against the current standard (Visionsense VS3 Iridium system) for patients with Ovarian cancer. The VS3 is and FDA approved device currently in phase 3 clinical trials at the University of Pennsylvania and other institutions in combination …
The overall prevalence of Ovarian Cancer in the United States according to the US SEER Registry is 182,710 women. Ovarian cancer also has the highest mortality rate of the gynecological cancers. The overall five-year survival rate is 45% and for Stages III and IV it is only 20-25%. The majority …
In this study, we are comparing the use of two different interventions, 1) a 6 week skills-based telehealth intervention that provides participants with support, knowledge, and skills for coping with fatigue, or 2) educational materials and resources, to help you manage your fatigue.
This study involves research of an investigational therapy called SynKIR-110. SynKIR-110 is CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient’s T cells (white blood cells that are a part of the immune system) are changed in a laboratory so they can …
The purpose of this research study is to learn about the safety and effectiveness of using ONM 100 to obtain images of primary tumors and metastatic lymph nodes in patients with solid tumors undergoing routine surgery. Adults at least 18 years of age with a Biopsy-confirmed diagnosis of primary or …
1 - 10 of 14
- 1
- 2
